Here are four of the most recent updates in care and detention:
- A more accurate Alzheimer’s blood detection test is on the horizon. The blood test accurately identified 96% of beta amyloid levels and found 97% of phosphorylated tau proteins in testing. Both are key biomarkers, unique to Alzheimer’s disease.
- Cleveland Clinic researchers found that Alzheimer’s is “a woman’s health issue,” due to distinguishing differences in immune function, cellular metabolism and communication between brain cells that make them more prone to developing the condition.
- Contaminated injections have been tied to cases of early Alzheimer’s and were given to about 27,000 children.
- Aduhelm, a drug that received accelerated approval from the FDA for Alzheimer’s treatment and showed success in early trials, has been discontinued by Biogen after multiple reports over its efficacy surfaced.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.